COCRYSTAL PHARMA, INC. Operating Lease, Payments
COCRYSTAL PHARMA, INC. (COCP) reported Operating Lease, Payments of $400.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-03-31
- COCRYSTAL PHARMA, INC. operating lease, payments for the quarter ending 2024-12-31 was $123.00K.
- COCRYSTAL PHARMA, INC. operating lease, payments for the quarter ending 2023-09-30 was $57.00K, a 9.62% increase year-over-year.
- COCRYSTAL PHARMA, INC. operating lease, payments for the quarter ending 2023-06-30 was $59.00K, a 13.46% increase year-over-year.
- COCRYSTAL PHARMA, INC. operating lease, payments for the quarter ending 2023-03-31 was $56.00K, a 12.00% increase year-over-year.
- COCRYSTAL PHARMA, INC. operating lease, payments for fiscal 2025 was $400.00K, a 50.94% increase from fiscal 2024.
- COCRYSTAL PHARMA, INC. operating lease, payments for fiscal 2024 was $265.00K.
- COCRYSTAL PHARMA, INC. operating lease, payments for fiscal 2022 was $209.00K, a 7.18% increase from fiscal 2021.
- COCRYSTAL PHARMA, INC. operating lease, payments for fiscal 2021 was $195.00K, a 10.17% increase from fiscal 2020.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2025-12-31 | $400.00K 10-K · filed 2026-03-31 | |||
| 2024-12-31 | $123.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $265.00K 10-K · filed 2026-03-31 | ||
| 2024-09-30 | $142.00K 10-Q · filed 2024-11-13 | |||
| 2023-09-30 | $57.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $116.00K derived: sum of 2 quarters · filed 2024-11-13 | $172.00K 10-Q · filed 2024-11-13 | $227.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $59.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $115.00K 10-Q · filed 2023-08-14 | $170.00K derived: sum of 3 quarters · filed 2023-08-14 | $222.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-03-31 | $56.00K 10-Q · filed 2023-05-15 | $111.00K derived: sum of 2 quarters · filed 2023-05-15 | $163.00K derived: sum of 3 quarters · filed 2023-11-13 | $215.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-12-31 | $55.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $107.00K derived: sum of 2 quarters · filed 2023-11-13 | $159.00K derived: sum of 3 quarters · filed 2023-11-13 | $209.00K 10-K · filed 2023-03-29 |
| 2022-09-30 | $52.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $104.00K derived: sum of 2 quarters · filed 2023-11-13 | $154.00K 10-Q · filed 2023-11-13 | $203.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $52.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $102.00K 10-Q · filed 2023-08-14 | $151.00K derived: sum of 3 quarters · filed 2023-08-14 | $200.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $50.00K 10-Q · filed 2023-05-15 | $99.00K derived: sum of 2 quarters · filed 2023-05-15 | $148.00K derived: sum of 3 quarters · filed 2023-05-15 | $197.00K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $49.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $98.00K derived: sum of 2 quarters · filed 2023-03-29 | $147.00K derived: sum of 3 quarters · filed 2023-03-29 | $195.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $49.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $98.00K derived: sum of 2 quarters · filed 2022-11-14 | $146.00K 10-Q · filed 2022-11-14 | $192.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $49.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $97.00K 10-Q · filed 2022-08-15 | $143.00K derived: sum of 3 quarters · filed 2022-08-15 | $187.00K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $48.00K 10-Q · filed 2022-05-11 | $94.00K derived: sum of 2 quarters · filed 2022-05-11 | $138.00K derived: sum of 3 quarters · filed 2022-05-11 | $181.00K derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $46.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $90.00K derived: sum of 2 quarters · filed 2022-03-23 | $133.00K derived: sum of 3 quarters · filed 2022-03-23 | $177.00K 10-K · filed 2022-03-23 |
| 2020-09-30 | $44.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $87.00K derived: sum of 2 quarters · filed 2021-11-15 | $131.00K 10-Q · filed 2021-11-15 | $170.00K derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $43.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $87.00K 10-Q · filed 2021-08-16 | $126.00K derived: sum of 3 quarters · filed 2021-08-16 | $167.00K derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | $44.00K 10-Q · filed 2021-05-17 | $83.00K derived: sum of 2 quarters · filed 2021-05-17 | $124.00K derived: sum of 3 quarters · filed 2021-05-17 | $150.00K derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | $39.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17 | $80.00K derived: sum of 2 quarters · filed 2021-03-17 | $106.00K derived: sum of 3 quarters · filed 2021-03-17 | $133.00K 10-K · filed 2021-03-17 |
| 2019-09-30 | $41.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $67.00K derived: sum of 2 quarters · filed 2020-11-13 | $94.00K 10-Q · filed 2020-11-13 | |
| 2019-06-30 | $26.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $53.00K 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $27.00K 10-Q · filed 2020-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |